Literature DB >> 7189263

Humoral immunity in myasthenia gravis: effect of steroids and thymectomy.

R S Tindall.   

Abstract

Antibody to the nicotinic acetylcholine receptor is detectable in most patients with myasthenia gravis and is responsible for the defect in neuromuscular transmission present in the disorder. We evaluated the effects of thymectomy and steroid therapies on antireceptor antibody titers. The thymectomy-treated group (consisting of juvenile and early adult-onset patients) experienced a variable change in postoperative antibody titers, ranging from a 28% increase to an 84% decrease, with the mean change of an 18.3% decrease. The steroid-treated group consisted of late adult-onset myasthenics. In these patients there was a decrease in antibody titer ranging from 29% to 83%. The average time required for a 50% reduction in titer was 4.85 months and was associated with a marked clinical improvement or complete remission.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7189263     DOI: 10.1212/wnl.30.5.557

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

2.  Immunoadsorption therapy for myasthenia gravis.

Authors:  N Shibuya; T Sato; M Osame; T Takegami; S Doi; S Kawanami
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

3.  Thymolipoma in association with late-onset myasthenia gravis.

Authors:  B Mikkelsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-02       Impact factor: 10.154

4.  [Correlation of acetylcholine receptor antibodies and clinical severity of myasthenia gravis in combined immunosuppressive therapy].

Authors:  F Schumm; A Fateh-Moghadam; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

Review 5.  A practical guide to the recognition and management of myasthenia gravis.

Authors:  A Evoli; A P Batocchi; P Tonali
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 6.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

7.  A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis.

Authors:  C W Olanow; A S Wechsler; A D Roses
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

Review 8.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

9.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12

10.  Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.

Authors:  H Link; O Olsson; J Sun; W Z Wang; G Andersson; H P Ekre; T Brenner; O Abramsky; T Olsson
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.